Table 1.
Characteristics of ciclesonide
| Method of delivery | HFA-MDI |
|---|---|
| Particle size27 | 1.1–2.1 μm |
| Pulmonary Deposition26 | 52% |
| Oral deposition26 | 38% |
| Systemic bioavailability30 | CIC = 18% Des-CIC = 50% |
| Serum protein binding (des-CIC)62 | ∼99%, <1% unbound fraction |
| Target tissue retention (des-CIC)25 | >24 hours |
| Mean terminal half-life (t1/2; des-CIC)27 | 3.5 hours |
| Elimination half-life (t1/2; CIC)27 | 0.71 hours |
Abbreviations: CIC, ciclesonide; des-CIC, desisobutyryl-ciclesonide; HFA-MDI, hydrofluoroalkane metered dose inhaler.